Cipla Ltd. — Capital/Financing Update 2019

Apr 1, 2019

pt April 2019

• (1) BSE Ltd Listing Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001
• (2) National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Dear Sirs,

We wish to inform that the Company's wholly owned subsidiary in USA i.e. Cipla Technologies LLC, has signed a binding term sheet today with Pulmatrix Inc., ("Pulmatrix") for an investment in Phase 2 ready asset co-development and licensing opportunity for Pulmazole (Inhaled ltraconazole) for an upfront consideration of USD 22 million. Entry into a definitive agreement is contingent upon Pulmatrix raising additional funds from the market. Upon signing the definitive agreement, the co-development cost towards development and the total free cash flow in relation to commercialization of Pulmazole will be further shared by both the parties in a phased manner.

Please take the above information on record.

Thank you,

For Cipla Limited

Rajendra Chopra Company Secretary

Prepared by: Kamlesh Kulkarni